Fabio Conforti

3.8k total citations · 2 hit papers
78 papers, 1.9k citations indexed

About

Fabio Conforti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Fabio Conforti has authored 78 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 17 papers in Neurology. Recurrent topics in Fabio Conforti's work include Cancer Immunotherapy and Biomarkers (20 papers), Myasthenia Gravis and Thymoma (17 papers) and Lung Cancer Treatments and Mutations (11 papers). Fabio Conforti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Myasthenia Gravis and Thymoma (17 papers) and Lung Cancer Treatments and Mutations (11 papers). Fabio Conforti collaborates with scholars based in Italy, United States and Spain. Fabio Conforti's co-authors include Laura Pala, Tommaso De Pas, Vincenzo Bagnardi, Giuseppe Viale, Richard D. Gelber, Aron Goldhirsch, Emilia Cocorocchio, Pier Francesco Ferrucci, Giuseppe Giaccone and Eleonora Pagan and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Cell.

In The Last Decade

Fabio Conforti

75 papers receiving 1.9k citations

Hit Papers

Cancer immunotherapy effi... 2018 2026 2020 2023 2018 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
    2018 666 citations Fabio Conforti, Laura Pala et al. profile →
  2. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
    2021 192 citations Pier Francesco Ferrucci, Laura Pala et al. Cancers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabio Conforti Italy 18 1.2k 522 398 390 232 78 1.9k
Dirk Behringer Germany 27 1.1k 0.9× 388 0.7× 630 1.6× 424 1.1× 112 0.5× 69 2.2k
Erin M. Bertino United States 20 1.2k 1.0× 508 1.0× 379 1.0× 134 0.3× 335 1.4× 73 1.8k
Emilia Cocorocchio Italy 19 1.2k 1.1× 320 0.6× 456 1.1× 481 1.2× 60 0.3× 65 1.8k
Fabio Bozzi Italy 21 526 0.5× 662 1.3× 602 1.5× 646 1.7× 190 0.8× 49 1.9k
Hussein Tawbi United States 24 1.1k 1.0× 694 1.3× 739 1.9× 382 1.0× 51 0.2× 108 2.0k
Roberta Camisa Italy 17 872 0.7× 289 0.6× 448 1.1× 364 0.9× 62 0.3× 44 1.5k
Hani M. Babiker United States 18 670 0.6× 375 0.7× 361 0.9× 166 0.4× 92 0.4× 154 1.5k
Lynn Navale United States 17 1.7k 1.4× 241 0.5× 387 1.0× 317 0.8× 137 0.6× 59 2.1k
Ulf Petrausch Switzerland 23 1.1k 0.9× 289 0.6× 289 0.7× 450 1.2× 61 0.3× 62 1.6k
Charlotte H. Ahern United States 22 756 0.6× 541 1.0× 798 2.0× 99 0.3× 571 2.5× 42 2.0k

Countries citing papers authored by Fabio Conforti

Since Specialization
Citations

This map shows the geographic impact of Fabio Conforti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Conforti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Conforti more than expected).

Fields of papers citing papers by Fabio Conforti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Conforti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Conforti. The network helps show where Fabio Conforti may publish in the future.

Co-authorship network of co-authors of Fabio Conforti

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Conforti. A scholar is included among the top collaborators of Fabio Conforti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Conforti. Fabio Conforti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valenza, Carmine, Dario Trapani, Francesca Porta, et al.. (2025). The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis. The Oncologist. 30(2). 1 indexed citations
2.
Conforti, Fabio, et al.. (2025). Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses. Cancers. 17(7). 1054–1054. 5 indexed citations
3.
Conforti, Fabio, Laura Pala, Tommaso De Pas, et al.. (2025). Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence. Journal of Clinical Oncology. 43(30). 3237–3244.
4.
Botteri, Edoardo, Fabio Conforti, Vincenzo Bagnardi, et al.. (2025). Aprepitant use during chemotherapy and association with survival in women with early breast cancer. JNCI Journal of the National Cancer Institute. 117(11). 2249–2258. 2 indexed citations
5.
Pala, Laura, Eleonora Pagan, Tommaso De Pas, et al.. (2024). “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”. The Breast. 73. 103672–103672. 1 indexed citations
6.
7.
Pas, Tommaso De, Giovanna Rossi, Paola Bossi, et al.. (2023). Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review. Current Oncology. 30(3). 3494–3499. 4 indexed citations
8.
Conforti, Fabio, Laura Pala, Tommaso De Pas, et al.. (2023). Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clinical Cancer Research. 30(6). 1093–1103. 1 indexed citations
9.
10.
Zagami, Paola, Alessandro Comandone, Marco Fiore, et al.. (2023). The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers. Cancer Medicine. 12(16). 17047–17055. 2 indexed citations
11.
Giugliano, Federica, Paolo Andrea Zucali, Giulia Galli, et al.. (2022). SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. European Journal of Cancer. 166. 202–207. 3 indexed citations
12.
Ceccacci, Elena, Fabio Conforti, Isabella Pallavicini, et al.. (2021). Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene. 41(6). 878–894. 20 indexed citations
13.
Pala, Laura, Fabio Conforti, Eleonora Pagan, et al.. (2021). Different Response to Immunotherapy According to Melanoma Histologic Subtype. Journal of Immunotherapy. 45(2). 119–124. 6 indexed citations
14.
Corso, Giovanni, Samuele Frassoni, Antonia Girardi, et al.. (2020). Metaplastic breast cancer: Prognostic and therapeutic considerations. Journal of Surgical Oncology. 123(1). 61–70. 34 indexed citations
15.
Cocorocchio, Emilia, Chiara Martinoli, Sara Gandini, et al.. (2020). Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. Clinical & Translational Oncology. 22(10). 1818–1824. 7 indexed citations
16.
Saponara, Maristella, Laura Pala, Fabio Conforti, et al.. (2020). Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology. 12. 3863592042–3863592042. 4 indexed citations
17.
18.
Conforti, Fabio, Laura Pala, Vincenzo Bagnardi, et al.. (2019). Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. 111(8). 772–781. 173 indexed citations
19.
Alberobello, Anna Teresa, Yisong Wang, Frans Beerkens, et al.. (2016). PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. Journal of Thoracic Oncology. 11(8). 1345–1356. 44 indexed citations
20.
Catania, Chiara, Edoardo Botteri, Massimo Barberis, et al.. (2015). Molecular Features and Clinical Outcome of Lung Malignancies in Very Young People. Future Oncology. 11(8). 1211–1221. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dirk Behringer Breakdown of academic impact, for papers by Erin M. Bertino Breakdown of academic impact, for papers by Emilia Cocorocchio Breakdown of academic impact, for papers by Fabio Bozzi Breakdown of academic impact, for papers by Hussein Tawbi Breakdown of academic impact, for papers by Roberta Camisa Breakdown of academic impact, for papers by Hani M. Babiker Breakdown of academic impact, for papers by Lynn Navale Breakdown of academic impact, for papers by Ulf Petrausch Breakdown of academic impact, for papers by Charlotte H. Ahern
Rankless by CCL
2026